Visceral fat is the fat that accumulates around the abdomen, where vital internal organs are present. This is the most dangerous type of extra fat a person can have. Visceral fat is also called metabolically active fat. It accumulates around the liver and pancreas and is a major contributor to disease.
The results of the Japanese study were announced at a meeting of the Association for the Study of Diabetes in Europe. The researchers examined the two types of fat that accumulate in the body, visceral fat and subcutaneous fat (the kind that accumulates under the skin). It was explained that when visceral fat accumulates, it can result in insulin resistance, type 2 diabetes, and cardiometabolic disease.
More than five hundred significantly overweight men and women participated in a study on the effects of Acomplia on visceral fat. At the end of the study, subjects taking Acomplia according to a regular dosing schedule had lost significantly more visceral fat than those taking a placebo pill.
Acomplia’s maker, Sanofi Aventis, tries to position Acomplia as more than just a weight-loss drug. The company says that the drug Acomplia may also help improve metabolic conditions, including diabetes. If they can get it recognized in this way, Acomplia will soon look more like a medicine and less like a cosmetic pill. In fact, the new findings on Acomplia may help get it approved for use in hospitals.
Today, Acomplia is known primarily as a weight loss aid. It works by interfering with the brain’s hunger signals, causing appetite suppression. You can buy Acomplia online in UK for more than one year. Acomplia is available in most of Europe on prescription.
